Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan – Biogen

1. Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan  Biogen
2. Eisai completes rolling submission to US FDA for LEQEMBI IQLIK supplemental biologics license application  Express Pharma
3. Bioarctic’s Partner Eisai Completes Application for Leqembi Iqlik in the United States  MarketScreener
4. Eisai completes FDA submission for Alzheimer’s treatment autoinjector  Investing.com
5. Eisai Completes FDA Submission for Home-Use Alzheimer’s Treatment  TipRanks

Continue Reading